Clinical Trial Update: A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression [Phase 3]

View source ↗

Summary

Phase 3 US study evaluating the safety and tolerability of Corlux for psychotic symptoms in psychotic major depression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Psychotic Disorders

Drugs mentioned

• CORLUX (mifepristone)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Major Depressive Disorder, Psychotic Disorders | Phase 3 | Status: COMPLETED